GJB2/GJB6 (Connexin 26/30) (Deafness Genetic Test)
| Order Code: | GJB2 |
| Epic Lab Code: | LAB7323 |
| Order Form: | A-1a Miscellaneous Request or Epic Req |
Commercial Mail-out Laboratory
6240 RCP
356-3527
6240 RCP
356-3527
Specimen:
Whole Blood
Collection Medium:
![]() | and | ![]() |
| Pink top tube | Pink top tube |
Alternate
Collection Media:
Lavender top tube 4 mL (EDTA)
Minimum:
Preferred Minimum: 8 mL whole blood
Absolute Minimum: 4 mL whole blood
Analytic Time:
8 weeks
Reference Range:
None detected
Interpretive Data:
DFNB1
Two different genes cause hearing loss at this locus, which maps to
chromosome 13q11-q12:GJB2, encoding Connexin 26; and GJB6, encoding
Connexin 30.
GJB2 (encodes Connexin 26, CX26)
CX26 is a gap junction protein expressed in the supporting cells of the
cochlea. The gene, GJB2, contains 2 exons, the second of which encodes
the 226 amino acid protein CX26. Mutations in GJB2 are found in ~50% of
persons with autosomal recessive nonsyndromic hearing loss. Over 100
different mutations have been identified.
GJB6 (encodes Connexin 30, CX30)
CX30 is also a gap junction protein. Lerer and colleagues identified a
deletion upstream of GJB2, which included the first exon of GJB6 in
2001. Del Castillo and colleagues characterized this deletion as a
342kb fragment of chromosome 13 that included D13S1830 in addition to a
portion of GJB6, and so this deletion is commonly known as the
del(GJB6-D13S1830) mutation. It cosegregates with mutations in GJB2 to
cause recessively inherited deafness at the DFNB1 locus. A recent
multicenter study investigating the mutation spectrum in over 1500 deaf
persons from 16 countries found this mutation to represent 1.67% of
mutations at the DFNB1 locus (Van Camp, et al. 2005). A second smaller
deletion, del(GJB6-D13S1854), also causes deafness at the DFNB1 locus.
Sensitivity is greater than 98%.
Comments:
Please print, complete and submit the Deafness Testing Requisition from the Molecular Otolaryngology
& Renal Research Laboratory, to Specimen Control/Mailouts with the
specimen and the Epic Requisition.
Methodology:
Over 97% of the identified mutations at the DFNB1 locus occur in exon 2
of GJB2 (Van Camp, et al 2005). We have adopted a tiered screening
process focusing first on exon 2 of GJB2 and the two GJB6-containing
deletions. The finding of two deafness-causing mutations is consistent
with the diagnosis of hearing loss at the DFNB1 locus. If one only
mutation is found, mutation screening for the splice site mutation in
exon 1 of GJB2 (IVS1 + 1 G>A) is completed. If no deafness-causing
mutations are found, the diagnosis of hearing loss at the DFNB1 locus
is excluded based on today’s standards. (GJB2 mutation screening is
performed by amplification of oligonucleotide primers that flank each
exon followed by bi-directional sequencing. Screening for the del(GJB6-
D13S1830) and del(GJB6-D13S1854) mutations is completed by PCR
amplification of oligonucleotide primers flanking and within the
deletion breakpoints. Products are run on agarose gel and sized to
determine presence or absence of a deletion.)
CPT Code:
83891, 83894, 83898 (x3), 83903, 83904 (x4)
